Vitiligo as durvalumab's immune-related adverse event in lung cancer
- PMID: 34674860
- DOI: 10.1016/j.medcli.2021.07.024
Vitiligo as durvalumab's immune-related adverse event in lung cancer
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical